Navigation Links
Statin does not appear helpful for children with learning disabilities caused by genetic disorder

Use of simvastatin by children with neurofibromatosis type 1 (NF1), a genetic disorder that can cause learning disabilities, did not result in improved cognitive function, according to a study in the July 16 issue of JAMA.

Characteristics of NF1 (incidence 1:3,000) include skin disorders, problems with small and large movement skills as well as the frequent occurrence of cognitive disabilities, such as visual-spatial skills, nonverbal long-term memory and attention span, according to background information in the article. Some NF1 studies involving mice suggested that use of a statin could improve cognitive deficits.

Lianne C. Krab, M.Sc., of Erasmus MC University Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands, and colleagues conducted a randomized trial to study the effect of the statin simvastatin on cognitive function of 62 children with NF1. The participants received simvastatin or placebo treatment once daily for 12 weeks.

After the treatment period, there was no significant difference between the simvastatin and placebo groups on several cognitive measures (determined by testing), including assessing nonverbal long-term memory, assessing attention and prism adaptation task (measurement of adaptation of the angle of hand movements in response to prism glass distortion, which is thought to be dependent on cerebellar function).

In the secondary outcome measures, the researchers found a significant improvement in the simvastatin group in object assembly scores, which was specifically observed in children with poor baseline performance. Other secondary outcome measures, such as attention fluctuations and a developmental test of visual-motor integration revealed no significant effect of simvastatin treatment.

"The negative outcome of this trial suggests that simvastatin should not be prescribed to ameliorate the cognitive deficits associated with NF1. Further studies to evaluate a longer treatment period and whether the object assembly finding is spurious may be warranted," the authors conclude.


Contact: Ype Elgersma, Ph.D.
JAMA and Archives Journals

Related biology news :

1. Natural compound in broccoli could treat devastating genetic skin disorder
2. Tigers disappear from Himalayan refuge
3. Californias wildflowers are disappearing, new book by UCR ecologist cautions
4. Mars water appears to have been too salty to support life
5. A Great Lakes mystery: The case of the disappearing species
6. Exposure to low levels of radon appears to reduce the risk of lung cancer, new study finds
7. A compound extracted from olives inhibits cancer cells growth and prevents their appearance
8. Wild chimpanzees appear not to regularly experience menopause
9. Humans appear hardwired to learn by over-imitation
10. Laser can spot illness before symptoms appear
11. Scientists identify embryonic stem cells by appearance alone
Post Your Comments:
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... SAN DIEGO , June 27, 2016  Sequenom, ... company committed to enabling healthier lives through the development ... Supreme Court of the United States ... Federal courts that the claims of Sequenom,s U.S. Patent ... the patent eligibility criteria established by the Supreme Court,s ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
Breaking Biology Technology: